172 related articles for article (PubMed ID: 24914850)
1. [Economic features of active surveillance].
Huguet J; Musquera M; Ribal MJ; Alcaraz A
Arch Esp Urol; 2014 Jun; 67(5):509-13. PubMed ID: 24914850
[TBL] [Abstract][Full Text] [Related]
2. The economics of active surveillance for prostate cancer.
Dall'Era MA
Curr Opin Urol; 2013 May; 23(3):278-82. PubMed ID: 23449496
[TBL] [Abstract][Full Text] [Related]
3. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
[TBL] [Abstract][Full Text] [Related]
4. Economic analysis of active surveillance for localized prostate cancer.
Kim S; Dall'Era MA; Evans CP
Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
[TBL] [Abstract][Full Text] [Related]
5. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.
Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM
Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive analysis of cost of an active surveillance cohort compared to radical prostatectomy as primary treatment for prostate cancer.
Pozo C; Hernández V; Capitán C; de la Peña E; Fernández-Conejo G; Martínez MDM; Del Riego S; Pérez-Fernández E; Llorente C
World J Urol; 2019 Jul; 37(7):1297-1303. PubMed ID: 30276542
[TBL] [Abstract][Full Text] [Related]
7. Managing localized prostate cancer by radical prostatectomy or watchful waiting: Cost analysis of a randomized trial (SPCG-4).
Andersson SO; Andrén O; Lyth J; Stark JR; Henriksson M; Adami HO; Carlsson P; Johansson JE
Scand J Urol Nephrol; 2011 Apr; 45(3):177-83. PubMed ID: 21265595
[TBL] [Abstract][Full Text] [Related]
8. A decision analysis comparing 3 active surveillance protocols for the treatment of patients with low-risk prostate cancer.
White C; Nimeh T; Gazelle GS; Weinstein MC; Loughlin KR
Cancer; 2019 Mar; 125(6):952-962. PubMed ID: 30561761
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of active surveillance compared to watchful waiting and radical prostatectomy for low risk localised prostate cancer.
Lao C; Edlin R; Rouse P; Brown C; Holmes M; Gilling P; Lawrenson R
BMC Cancer; 2017 Aug; 17(1):529. PubMed ID: 28789623
[TBL] [Abstract][Full Text] [Related]
10. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
11. Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer.
Corcoran AT; Peele PB; Benoit RM
Urology; 2010 Sep; 76(3):703-7. PubMed ID: 20381846
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review.
Becerra V; Ávila M; Jimenez J; Cortes-Sanabria L; Pardo Y; Garin O; Pont A; Alonso J; Cots F; Ferrer M;
BMC Health Serv Res; 2016 Oct; 16(1):541. PubMed ID: 27716267
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Active Surveillance, Radical Prostatectomy and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial.
Sharma V; Wymer KM; Borah BJ; Barocas DA; Thompson RH; Karnes RJ; Boorjian SA
J Urol; 2019 Nov; 202(5):964-972. PubMed ID: 31112105
[TBL] [Abstract][Full Text] [Related]
14. Treatment options for localized prostate cancer.
Mohan R; Schellhammer PF
Am Fam Physician; 2011 Aug; 84(4):413-20. PubMed ID: 21842788
[TBL] [Abstract][Full Text] [Related]
15. Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies.
Muralidhar V; Nguyen PL
Urol Oncol; 2017 Feb; 35(2):76-85. PubMed ID: 27473636
[TBL] [Abstract][Full Text] [Related]
16. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis.
Keegan KA; Dall'Era MA; Durbin-Johnson B; Evans CP
Cancer; 2012 Jul; 118(14):3512-8. PubMed ID: 22180322
[TBL] [Abstract][Full Text] [Related]
17. [Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study].
Reinhold T; Dornquast C; Börgermann C; Weißbach L
Urologe A; 2016 Dec; 55(12):1573-1585. PubMed ID: 27822603
[TBL] [Abstract][Full Text] [Related]
18. Words of wisdom. Re: Active surveillance for prostate cancer compared with immediate treatment: an economic analysis.
Klaassen Z; Wyatt B; Moses KA; Terris MK
Eur Urol; 2013 Nov; 64(5):855. PubMed ID: 24112612
[No Abstract] [Full Text] [Related]
19. An economic analysis of conservative management versus active treatment for men with localized prostate cancer.
Perlroth DJ; Bhattacharya J; Goldman DP; Garber AM
J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):250-7. PubMed ID: 23271781
[TBL] [Abstract][Full Text] [Related]
20. How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer?
Snyder CF; Frick KD; Blackford AL; Herbert RJ; Neville BA; Carducci MA; Earle CC
Cancer; 2010 Dec; 116(23):5391-9. PubMed ID: 20734396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
